Skip to content
Screener

Alkermes ALKS Investing Cash Flow

Investing Cash Flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
-$1.61B-241%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$123.1M+173%
AbbVie logo
AbbVieABBV
-$574M+21.9%
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
-$121K+64.2%
Indivior Pharmaceuticals, Inc. logo
Indivior Pharmaceuticals, Inc.INDV
-$19M-280%
LBR
LB Pharmaceuticals IncLBRX
-$32K-101%

Other financials

Income statement

See full
Revenue$496.0M+27.0%
Gross profit$397.9M+16.6%
Operating income$18.4M-80.3%
Net income$501.0K-99.4%
EPS (diluted)$0.00-100%

Balance sheet

See full
Cash & equivalents$511.5M-1.9%
Total debt$1.6B+2,064%
Total equity$1.8B+11.3%
Total assets$4.4B+95.0%

Cash flow

See full
Operating cash flow-$165.7M-268%
CapEx$8.1M-37.4%
Free cash flow-$169.8M-291%

Valuation

See full
Market cap$8.32B+89.9%
Enterprise value$9.38B+139%
P/E125.9×+113×
P/S+2.1×

Profitability

See full
Gross margin84.6%-0.6pp
Operating margin7%-17.8pp
Net margin4%-19.2pp
FCF margin14.2%-17.6pp

Returns & leverage

See full
Return on equity3.9%-20.1pp
Debt / equity0.9×+0.8×
Current ratio2.3×-0.9×

Where this comes from

Reported directly by Alkermes in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The source filing: Alkermes’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 9:22 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-319022
Line itemSix Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Business combination, net of cash acquired(2,085,073)
Purchases of investments(44,804)(193,806)
Sales and maturities of investments62,693195,078
Cash flows used in investing activities(2,079,411)(20,112)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from the issuance of ordinary shares under share-based compensation arrangements42,00631,611
Proceeds from the issuance of debt, net1,511,557
Deferred financing costs paid to third parties(2,980)

Item 1. Condensed Consolidated Financial Statements:

FAQ

What is Alkermes's investing cash flow?
Alkermes (ALKS) reported investing cash flow of -$2.41M in Q2 2026.
How has Alkermes's investing cash flow changed year-over-year?
Alkermes's investing cash flow increased by 91.7% year-over-year, from -$29.21M to -$2.41M.
What is the long-term trend for Alkermes's investing cash flow?
Over 2 years (2021 to 2025), Alkermes's investing cash flow has grown at a 105.2% compound annual growth rate (CAGR), from -$70.18M to $295.5M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Ask your AI about Alkermes's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude